CO6351800A2 - Anticuerpos anti -il -17a/il -17f de reactividad cruzada y metodos de uso de los mismos - Google Patents

Anticuerpos anti -il -17a/il -17f de reactividad cruzada y metodos de uso de los mismos

Info

Publication number
CO6351800A2
CO6351800A2 CO10152119A CO10152119A CO6351800A2 CO 6351800 A2 CO6351800 A2 CO 6351800A2 CO 10152119 A CO10152119 A CO 10152119A CO 10152119 A CO10152119 A CO 10152119A CO 6351800 A2 CO6351800 A2 CO 6351800A2
Authority
CO
Colombia
Prior art keywords
methods
same
homodimer
monoclonal antibodies
reactivity
Prior art date
Application number
CO10152119A
Other languages
English (en)
Spanish (es)
Inventor
Krzystof Masternak
Olivier Leger
Original Assignee
Novimmune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41265089&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6351800(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novimmune Sa filed Critical Novimmune Sa
Publication of CO6351800A2 publication Critical patent/CO6351800A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CO10152119A 2008-05-05 2010-12-02 Anticuerpos anti -il -17a/il -17f de reactividad cruzada y metodos de uso de los mismos CO6351800A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12646508P 2008-05-05 2008-05-05
US9836908P 2008-09-19 2008-09-19

Publications (1)

Publication Number Publication Date
CO6351800A2 true CO6351800A2 (es) 2011-12-20

Family

ID=41265089

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10152119A CO6351800A2 (es) 2008-05-05 2010-12-02 Anticuerpos anti -il -17a/il -17f de reactividad cruzada y metodos de uso de los mismos

Country Status (19)

Country Link
US (4) US20090317400A1 (enExample)
EP (1) EP2288382B1 (enExample)
JP (4) JP2011519911A (enExample)
KR (5) KR101711798B1 (enExample)
CN (2) CN102083858B (enExample)
AU (1) AU2009245440C1 (enExample)
BR (1) BRPI0908312A2 (enExample)
CA (1) CA2721713C (enExample)
CO (1) CO6351800A2 (enExample)
EC (1) ECSP10010653A (enExample)
HK (1) HK1210484A1 (enExample)
IL (2) IL208808A (enExample)
MA (1) MA32365B1 (enExample)
MX (2) MX2010012090A (enExample)
NZ (3) NZ588674A (enExample)
RU (2) RU2474588C2 (enExample)
SG (2) SG10201608871XA (enExample)
WO (1) WO2009136286A2 (enExample)
ZA (1) ZA201007452B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX341074B (es) 2003-07-08 2016-08-05 Genentech Inc Polipeptidos heterologos il-17 a/f y usos terapeuticos de los mismos.
US20110256142A1 (en) * 2007-09-06 2011-10-20 Genmab A/S Novel methods and antibodies for treating cancer
NZ588674A (en) 2008-05-05 2013-02-22 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
US8790642B2 (en) 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
SG175276A1 (en) * 2009-05-05 2011-11-28 Novimmune Sa Anti-il-17f antibodies and methods of use thereof
JP5913103B2 (ja) 2009-09-14 2016-04-27 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ 酵母ベースの免疫療法組成物を含む組合せ物及び被験者のスクリーニング方法
ES2701626T3 (es) * 2009-12-28 2019-02-25 Oncotherapy Science Inc Anticuerpos anti-CDH3 y sus usos
US20130046015A1 (en) * 2010-02-11 2013-02-21 Robert C. Axtell Therapeutic Inhibition of Granulocyte Function in Demyelinating Disease
AU2011249908A1 (en) * 2010-05-06 2012-11-22 Singulex, Inc. Methods for diagnosing, staging, predicting risk for developing and identifying treatment responders for rheumatoid arthritis
RU2012149227A (ru) 2010-05-20 2014-06-27 Аблинкс Нв Биологические материалы, относящиеся к her3
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
AU2012206431B2 (en) 2011-01-14 2015-04-30 UCB Biopharma SRL Antibody molecules which bind IL-17A and IL-17F
US9345742B2 (en) 2011-02-08 2016-05-24 Merck Patent Gmbh Aminostatin derivatives for the treatment of arthrosis
UA117218C2 (uk) * 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
US9475872B2 (en) * 2011-12-28 2016-10-25 Immunoqure Ag Nucleic acid molecules encoding moonoclonal antibodies speceific for IL17F
US10131709B2 (en) 2011-12-28 2018-11-20 Immunoqure Ag Nucleic acid molecules encoding monoclonal antibodies specific for IL-22
JP6362587B2 (ja) 2012-05-22 2018-07-25 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｉｌ−１７ａ／ｆｉｌ−２３二重特異性抗体およびその使用
EP2864355B1 (en) 2012-06-25 2016-10-12 Orega Biotech Il-17 antagonist antibodies
ES2915378T3 (es) 2013-09-13 2022-06-22 Hoffmann La Roche Procedimientos para detectar y cuantificar una proteína de célula huésped en líneas celulares
KR102571391B1 (ko) 2013-09-13 2023-08-29 제넨테크, 인크. 정제된 재조합 폴리펩티드를 포함하는 방법 및 조성물
PL3072905T3 (pl) * 2013-11-18 2021-03-08 Shanghai Hengrui Pharmaceutical Co., Ltd. Środek wiążący il-17a i jego zastosowania
MX2016010729A (es) 2014-02-21 2016-10-26 Genentech Inc Anticuerpos biespecificos anti-il-13 / il-17 y sus usos.
EP3212665A2 (en) 2014-10-31 2017-09-06 F. Hoffmann-La Roche AG Anti-il-17a and il-17f cross reactive antibody variants and compositions comprising and methods of making and using same
RU2739500C2 (ru) 2014-11-05 2020-12-25 Дженентек, Инк. Способы получения двуцепочечных белков в бактериях
CN108064308B (zh) 2014-11-05 2023-06-09 豪夫迈·罗氏有限公司 细菌中产生双链蛋白的方法
DK4141032T3 (da) 2014-11-20 2024-08-05 Hoffmann La Roche Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler og PD-1-aksebindende antagonister
RU2017122172A (ru) * 2014-12-15 2019-01-17 МорфоСис АГ Антитела к IL-17C
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
JP2018506275A (ja) 2015-01-28 2018-03-08 ジェネンテック， インコーポレイテッド 多発性硬化症の遺伝子発現マーカー及び治療
CA2977285A1 (en) * 2015-03-16 2016-09-22 F. Hoffmann-La Roche Ag Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
JP6871919B2 (ja) 2015-06-16 2021-05-19 ナノファギックス エルエルシー 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法
EP3322716B1 (en) * 2015-07-15 2025-02-12 California Institute of Technology Il-17f-specific capture agents and methods of using
WO2017031476A2 (en) * 2015-08-20 2017-02-23 Genentech, Inc. Purification of fkpa and uses thereof for producing recombinant polypeptides
CN108350068A (zh) 2015-10-27 2018-07-31 Ucb生物制药私人有限公司 使用抗-il-17a/f抗体的治疗方法
GB201522391D0 (en) * 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibody molecules
RU2680011C2 (ru) * 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
CN107488227A (zh) * 2016-06-12 2017-12-19 三生国健药业（上海）股份有限公司 抗人白细胞介素‑17a单克隆抗体、其制备方法和应用
TN2019000082A1 (en) 2016-09-14 2020-07-15 Beijing hanmi pharm co ltd Antibody specifically binding to il-17a and functional fragment thereof
TWI778018B (zh) 2017-02-10 2022-09-21 美商建南德克公司 抗類胰蛋白酶抗體、其組合物及其用途
US10858427B2 (en) 2017-03-10 2020-12-08 Suzhou Kanova Biopharmaceutical Co., Ltd. Monoclonal antibody against both IL-17A and IL-17F and use of the same
WO2019087133A1 (en) 2017-11-02 2019-05-09 Novartis Ag Method of treating tendinopathy using interleukin-17 (il-17)
US11161900B2 (en) * 2018-12-13 2021-11-02 Argenx Bvba Antibodies that specifically bind to human complement factor C2b
JP7643727B2 (ja) * 2019-02-02 2025-03-11 華輝安健(北京)生物科技有限公司 抗－ｆｇｆ１９抗体
IL297689A (en) * 2020-04-30 2022-12-01 Janssen Pharmaceutica Nv Methods of identifying modulators of the il-17 pathway
KR20240043784A (ko) * 2021-08-09 2024-04-03 메르크 파텐트 게엠베하 염증유발성 시토카인의 방출로부터 t 세포-매개 종양 세포독성을 디커플링시키는 단백질
IL317086A (en) 2022-05-16 2025-01-01 Novartis Ag Methods of treating giant cell arteritis using interleukin-17 (il-17) antagonists
CA3257386A1 (en) 2022-05-18 2023-11-23 Novartis Ag METHOD FOR TREATING TENDINOPATHY USING INTERLEUKIN-17 (IL-17) ANTAGONISTS
EP4393948A1 (en) * 2022-12-28 2024-07-03 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Therapeutic vhh antibodies cross-neutralizing the il-17a and il-17f homodimers as well as the il-17af heterodimer
WO2025202213A1 (en) 2024-03-26 2025-10-02 Institut National de la Santé et de la Recherche Médicale Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4738681A (en) * 1985-07-10 1988-04-19 Harrington Arthritis Research Center Femoral-joint prosthetic device
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5370870A (en) * 1989-10-06 1994-12-06 Genentech, Inc. Method for protection against reactive oxygen species
SE500903C2 (sv) 1989-12-20 1994-09-26 Atlas Copco Constr & Mining Bergborrningsrigg
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5364839A (en) 1990-06-18 1994-11-15 Genetics Institute, Inc. Osteoinductive pharmaceutical formulations
US5206023A (en) 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
US5273033A (en) * 1991-09-19 1993-12-28 Murray Electronics Associates Limited Partnership Electrical stimulation for treatment of osteoarthritis
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
AU4231393A (en) * 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
GB9214857D0 (en) 1992-07-13 1992-08-26 Medical Res Council Human nucleic acid fragments and their use
US5536637A (en) * 1993-04-07 1996-07-16 Genetics Institute, Inc. Method of screening for cDNA encoding novel secreted mammalian proteins in yeast
US6274711B1 (en) * 1993-06-14 2001-08-14 Inserm, Institut National De La Sante Et De La Recherche Medicale Purified mammalian CTLA-8 antigens and related reagents
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
US5830877A (en) 1993-08-26 1998-11-03 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
US5444047A (en) * 1994-06-16 1995-08-22 Dipasquale; Gene Treatment of arthritic and post-surgical orthopedic conditions with Insulin-like Growth Factor-I
WO2001016318A2 (en) 1999-09-01 2001-03-08 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000073452A2 (en) 1999-06-02 2000-12-07 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP4373495B2 (ja) 1995-03-23 2009-11-25 イミュネックス・コーポレーション Ｉｌ−１７受容体
US5573762A (en) * 1995-04-24 1996-11-12 Genentech, Inc. Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy
EP0839196B1 (en) 1995-07-19 2005-05-11 Genetics Institute, LLC Human ctla-8 and uses of ctla-8-related proteins
US6074849A (en) * 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
US5707829A (en) 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
US6902735B1 (en) 1995-07-19 2005-06-07 Genetics Institute, Llc Antibodies to human IL-17F and other CTLA-8-related proteins
AU1407997A (en) 1995-12-01 1997-06-19 Beth Israel Hospital Il-12 p40 subunit fusion polypeptides and uses thereof
CN1211279A (zh) 1996-01-10 1999-03-17 科里克萨有限公司 用于治疗和诊断乳腺癌的组合物和方法
EP0959897B1 (en) 1996-11-27 2009-04-22 Immunex Corporation Method of regulating nitric oxide production
US6054559A (en) * 1997-01-28 2000-04-25 Smithkline Beecham Corporation Interleukin-1 receptor antagonist beta (IL-1raβ)
WO2001018022A1 (en) 1999-09-03 2001-03-15 Human Genome Sciences, Inc. 52 human secreted proteins
US20020177188A1 (en) * 1998-05-15 2002-11-28 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
WO2000053752A2 (en) 1999-03-08 2000-09-14 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
US6569645B2 (en) * 1999-05-14 2003-05-27 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US6579520B2 (en) * 1998-05-15 2003-06-17 Genentech, Inc. IL-17 related mammalian cytokine polypeptides (IL-17E)
EA199900869A1 (ru) 1997-04-25 2000-12-25 Займодженетикс, Инк. Цитокин-подобный фактор 7 млекопитающих
EP1012260A4 (en) 1997-07-16 2001-05-09 Human Genome Sciences Inc INTERLEUKINE-20
PE20000183A1 (es) 1997-07-25 2000-03-11 Schering Corp Citoquinas de mamiferos y reactivos relacionados
US6060284A (en) * 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
AU9482498A (en) 1997-09-17 1999-04-05 Human Genome Sciences, Inc. Interleukin-17 receptor-like protein
US6482923B1 (en) 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
US6562578B1 (en) * 1999-01-11 2003-05-13 Schering Corporation IL-17-like cytokine binding compounds and antibodies
WO1999032632A1 (en) 1997-12-19 1999-07-01 Millennium Pharmaceuticals, Inc. Novel embryo-derived interleukin related factor molecules and uses therefor
CA2314357A1 (en) 1997-12-19 1999-07-01 American Home Products Corporation Transgenic animal model for degenerative diseases of cartilage
WO1999035267A1 (en) 1998-01-09 1999-07-15 Immunex Corporation Human and murine il-17d, cytokine related to interleukin-17: dna and polypeptides
JP3868740B2 (ja) 1998-03-10 2007-01-17 ジェネンテック・インコーポレーテッド 新規なポリペプチド及びそれをコードする核酸
NZ528703A (en) 1998-03-25 2005-05-27 Genentech Inc Novel PRO337 polypeptides and nucleic acids encoding a neurotrimin polypeptide
CA2323929C (en) 1998-04-03 2004-03-09 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
EP1072610B1 (en) * 1998-04-14 2010-07-21 Chugai Seiyaku Kabushiki Kaisha Novel cytokine-like protein
US7771719B1 (en) * 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
PT1076703E (pt) * 1998-05-15 2007-10-10 Genentech Inc ''utilizações terapêuticas de polipéptido homólogos de il-17''
US20050147609A1 (en) 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
EP1443055A3 (en) 1998-05-29 2005-06-08 Human Genome Sciences, Inc. Interleukins-21 and 22
US20010023070A1 (en) 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
CA2329274A1 (en) * 1998-05-29 1999-12-02 Steven M. Ruben Interleukin-21
ES2300154T3 (es) 1998-09-17 2008-06-01 Zymogenetics, Inc. Factor de crecimiento de transformacion beta-9 en mamiferos (ztgfss9).
AU6277799A (en) 1998-10-02 2000-04-26 Eli Lilly And Company Il-17 homolog nucleic acids, polypeptides, vectors, host cells, methods and usesthereof
JP2000186046A (ja) 1998-10-14 2000-07-04 Snow Brand Milk Prod Co Ltd 慢性関節リウマチ治療剤及び診断方法
AU3207000A (en) 1999-01-11 2000-08-01 Schering Corporation Interleukin-17 related mammalian cytokine (il-171). polynucleotides encoding them. uses
DE60043051D1 (de) 1999-01-11 2009-11-12 Schering Corp Dafür kodierende polynukleotide. verwendungen
EP2319870A3 (en) 1999-03-25 2011-10-26 Abbott GmbH & Co. KG Human antibodies that bind human IL-12 and methods for producing
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
AU3632600A (en) 1999-05-14 2000-12-05 Genentech Inc. Compositions and methods for the treatment of immune related diseases
US20030082734A1 (en) * 1999-06-01 2003-05-01 Dowling Lynette M. Mammalian receptor proteins; related reagents and methods
US20030199041A1 (en) * 1999-07-07 2003-10-23 Presnell Scott R. Interleukin-17 receptor homologue
ES2364086T3 (es) 1999-07-07 2011-08-24 Zymogenetics, Inc. Receptor de citoquina humana.
WO2001012659A2 (en) 1999-08-18 2001-02-22 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Human dna sequences
AU7445900A (en) * 1999-09-27 2001-04-30 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, nr12
AU3434601A (en) 1999-11-30 2001-06-12 Genentech Inc. Compositions and methods for the treatment of immune related diseases
US20040043397A1 (en) * 2000-01-11 2004-03-04 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
EP1240325B1 (en) 1999-12-23 2009-09-30 Genentech, Inc. Il-17 and il-17r homologous polypeptides and therapeutic uses thereof
US6380362B1 (en) 1999-12-23 2002-04-30 Genesis Research & Development Corporation Ltd. Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use
US20040034192A1 (en) 2000-01-06 2004-02-19 Seishi Kato Human proteins having hyprophobic domains and dnas encoding these proteins
AU2001233041A1 (en) 2000-01-25 2001-08-07 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2001236638A1 (en) 2000-02-04 2001-08-14 The Board Of Trustees Of The University Of Arkansas Evi27 gene sequences and protein encoded thereby
AU6802801A (en) 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7094566B2 (en) * 2000-03-16 2006-08-22 Amgen Inc., IL-17 receptor like molecules and uses thereof
EP1266002A2 (en) 2000-03-16 2002-12-18 Amgen Inc., Il-17 receptor like molecules and uses thereof
AR030554A1 (es) 2000-03-16 2003-08-27 Amgen Inc Moleculas similares a receptores il-17 y usos de las mismas
ES2266187T3 (es) * 2000-03-24 2007-03-01 Genentech, Inc. Uso de la insulina para el tratamiento de trastornos del cartilago.
US6479636B1 (en) 2000-04-11 2002-11-12 Honiron Corporation (A Louisiana Corporation) Sugarcane fractioning system
CA2406245A1 (en) 2000-04-18 2001-10-25 Schering Corporation Il-174 uses, compositions and methods
US7422743B2 (en) * 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
CA2408571C (en) * 2000-05-10 2014-04-29 Schering Corporation Mammalian receptor proteins; related reagents and methods
AU2001274920A1 (en) 2000-05-24 2001-12-03 Schering Corporation Mammalian receptor proteins; related reagents and methods
US20030096969A1 (en) * 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU6531101A (en) 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2002008285A2 (en) 2000-06-22 2002-01-31 Amgen, Inc. Il-17 molecules and uses thereof
JP2004506413A (ja) 2000-06-23 2004-03-04 ジェネンテック・インコーポレーテッド 血管形成に関与する疾患の診断と治療のための組成物と方法
JP2004514420A (ja) 2000-07-20 2004-05-20 ジェネンテック・インコーポレーテッド 分泌及び膜貫通ポリペプチドとそれをコードする核酸
AU2001271973A1 (en) 2000-07-20 2002-02-05 Kevin P. Baker Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
CA2427824A1 (en) 2000-07-26 2002-01-31 Zymogenetics, Inc. Human cytokine receptor
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
JP2002139499A (ja) * 2000-08-23 2002-05-17 Sanyo Electric Co Ltd 化学物質センサおよび化学物質の検出方法
JP2002076897A (ja) * 2000-08-29 2002-03-15 Toshiba Corp Ｄａコンバータ
ES2277947T3 (es) 2000-10-13 2007-08-01 Eli Lilly And Company Procedimientos de uso de un polipeptido afin a il-17 humana para tratar enfermedades.
GB2372464B (en) 2001-02-22 2003-05-14 Vivascience Ltd Method of isolating a charged compound
US20070160576A1 (en) * 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
PL374118A1 (en) * 2001-08-07 2005-10-03 Immunex Corporation Interleukin-1 receptors in the treatment of diseases
JP2005506342A (ja) 2001-10-15 2005-03-03 ジェネンテック・インコーポレーテッド インスリン耐性状態の治療及び診断
US7103929B2 (en) * 2002-03-12 2006-09-12 Little Rapids Corporation Disposable bedding with absorbent region
WO2004042009A2 (en) 2002-10-30 2004-05-21 Genentech, Inc. Inhibition of il-17 production
TWI439285B (zh) * 2003-03-10 2014-06-01 Merck Sharp & Dohme Ｉｌ－２３激動劑及拮抗劑之用途及相關試劑
ATE490275T1 (de) 2003-06-23 2010-12-15 Genetics Inst Llc Antikörper gegen interleukin-22 und verwendungen dafür
MX341074B (es) 2003-07-08 2016-08-05 Genentech Inc Polipeptidos heterologos il-17 a/f y usos terapeuticos de los mismos.
CA2545258A1 (en) * 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Pyridine compounds
WO2005046698A1 (en) * 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Fused heterocyclic compounds
AU2004289305A1 (en) 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Heteroaryl-Hydrazone compounds
JP4833850B2 (ja) 2003-11-21 2011-12-07 ユセベ ファルマ ソシエテ アノニム Ｉｌ−１７活性阻害による多発性硬化症を治療するための方法
JP4903061B2 (ja) * 2004-02-17 2012-03-21 シェーリング コーポレイション Ｉｌ−２３活性を調節する方法；関連する試薬
US20050287593A1 (en) 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
CN1993480A (zh) 2004-05-03 2007-07-04 先灵公司 Il－17表达预测皮肤炎症的用途；治疗方法
US7910540B2 (en) * 2004-06-10 2011-03-22 Zymogenetics, Inc. Soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners and methods of using in inflammation
US7629691B2 (en) 2004-06-16 2009-12-08 Honeywell International Inc. Conductor geometry for electronic circuits fabricated on flexible substrates
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
AR051444A1 (es) * 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
EP1819731A4 (en) 2004-12-08 2013-02-13 Immunomedics Inc METHOD AND COMPOSITION FOR IMMUNOTHERAPY AND FOR THE DETECTION OF INFLAMMATORY AND DYSEGRATIVE IMMUNE DISEASES, INFECTION DISEASES, PATHOLOGICAL ANGIOGENESIS AND CANCER
TW200641353A (en) * 2005-02-14 2006-12-01 Wyeth Corp Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor
AU2006255686A1 (en) 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
EP2116258A1 (en) 2005-09-01 2009-11-11 Schering Corporation Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
US20070249533A1 (en) 2005-09-28 2007-10-25 Levin Steven D Il-17a and il-17f antagonists and methods of using the same
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
DK1963368T6 (da) 2005-12-13 2020-06-29 Lilly Co Eli Anti-il-17-antistoffer
US7981937B2 (en) * 2006-01-11 2011-07-19 Aurora Specialty Chemistries Corp. Aurora Stable dispersion of DBNPA in viscosified brine
WO2007117749A2 (en) 2006-01-31 2007-10-18 Novartis Ag Il-17 antagonistic antibodies fpr treating cancer
EP1996622A2 (en) 2006-03-10 2008-12-03 Zymogenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
US7790163B2 (en) * 2006-03-10 2010-09-07 Zymogenetics, Inc. Antibodies that bind both IL-17A and IL-17F and methods of using the same
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
JP2009540018A (ja) 2006-06-13 2009-11-19 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
CA2679588A1 (en) 2007-03-26 2008-10-02 Zymogenetics, Inc. Soluble il-17ra/rc fusion proteins and related methods
EP2150564A2 (en) 2007-04-27 2010-02-10 ZymoGenetics, Inc. Antagonists to il-17a, il-17f, and il-23p19 and methods of use
WO2008133684A1 (en) * 2007-04-27 2008-11-06 Zymogenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
BRPI0813262A2 (pt) 2007-06-20 2015-04-14 Schering Corp Biomarcadores de destruição de articulação para terapia de doença inflamatória de articulação anti-il-17a
ES2614735T3 (es) 2007-07-23 2017-06-01 Janssen Biotech, Inc. Métodos y composiciones para tratar los trastornos relacionados con fibrosis usando antagonistas de la IL-17
US20110300154A1 (en) 2007-08-21 2011-12-08 Children's Medical Center Corporation Treatment of airway hyperreactivity
GB0807413D0 (en) * 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
NZ588674A (en) 2008-05-05 2013-02-22 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
US8790642B2 (en) 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
WO2010114859A1 (en) 2009-04-01 2010-10-07 Genentech, Inc. Treatment of insulin-resistant disorders
SG175276A1 (en) 2009-05-05 2011-11-28 Novimmune Sa Anti-il-17f antibodies and methods of use thereof

Also Published As

Publication number Publication date
EP2288382B1 (en) 2018-08-29
WO2009136286A2 (en) 2009-11-12
SG10201608871XA (en) 2016-12-29
US8771697B2 (en) 2014-07-08
RU2012151478A (ru) 2014-06-10
CA2721713C (en) 2019-07-09
NZ588674A (en) 2013-02-22
KR20160028505A (ko) 2016-03-11
BRPI0908312A2 (pt) 2015-08-18
AU2009245440C1 (en) 2013-03-14
NZ600584A (en) 2014-05-30
US20120269820A1 (en) 2012-10-25
SG190626A1 (en) 2013-06-28
EP2288382A2 (en) 2011-03-02
CA2721713A1 (en) 2009-11-12
JP2014001217A (ja) 2014-01-09
CN104628855A (zh) 2015-05-20
KR101711798B1 (ko) 2017-03-02
AU2009245440A1 (en) 2009-11-12
HK1210484A1 (en) 2016-04-22
US20130195872A1 (en) 2013-08-01
KR101508086B1 (ko) 2015-04-07
KR20110025649A (ko) 2011-03-10
US8715669B2 (en) 2014-05-06
WO2009136286A3 (en) 2010-06-10
US20120141492A1 (en) 2012-06-07
NZ623706A (en) 2015-12-24
JP5898653B2 (ja) 2016-04-06
WO2009136286A9 (en) 2010-04-22
KR20150002874A (ko) 2015-01-07
RU2010149746A (ru) 2012-06-20
US20090317400A1 (en) 2009-12-24
IL208808A0 (en) 2011-01-31
MX355256B (es) 2018-04-11
JP2011519911A (ja) 2011-07-14
US9650437B2 (en) 2017-05-16
CN102083858B (zh) 2015-01-14
JP2017048191A (ja) 2017-03-09
RU2474588C2 (ru) 2013-02-10
CN102083858A (zh) 2011-06-01
KR20170023209A (ko) 2017-03-02
JP2015166355A (ja) 2015-09-24
IL208808A (en) 2015-04-30
KR20130138354A (ko) 2013-12-18
MA32365B1 (fr) 2011-06-01
JP6507133B2 (ja) 2019-04-24
ECSP10010653A (es) 2011-02-28
IL238051A0 (en) 2015-05-31
AU2009245440B2 (en) 2012-08-02
MX2010012090A (es) 2011-04-11
ZA201007452B (en) 2012-01-25

Similar Documents

Publication Publication Date Title
CO6351800A2 (es) Anticuerpos anti -il -17a/il -17f de reactividad cruzada y metodos de uso de los mismos
AR061246A1 (es) Anticuerpos anti- dill4 y metodos que los usan
CO2021001893A2 (es) Anticuerpos anti-gdf15, composiciones y métodos de uso
GT201200132A (es) Antagonistas il-17a
CR11017A (es) Anticuerpos anti-robo4 y sus usos
PA8718601A1 (es) Anticuerpos anti-5t4 y sus usos
BR112018014615A2 (pt) composições de anticorpo para ror1 e métodos relacionados
CR20120312A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
AR076655A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b
SV2008002972A (es) Composiciones, metodos y usos de anticuerpos humanos anti-il-23 ref. cen5117sv
CY1112277T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
TR201821029T4 (tr) Geliştirilmiş antı-IL-23p19 antikorları.
CL2007003622A1 (es) Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
PH12014502641A1 (en) Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
AR119997A1 (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso
CU20130023A7 (es) Anticuerpos para el receptor 3 del factor de crecimiento epidérmico(her3)
MX2021007768A (es) Anticuerpos anti-ctla4 y metodos de uso de los mismos.
CR20120587A (es) Moléculas de unión al antígeno que fijan egfr, vectores que las codifican y uso de las mismas
UY37591A (es) Conjugados de fármaco anticuerpo
CR20160355A (es) Anticuerpos neutralizantes de atomegalovirus humanos y uso de los mismos
CO2023018064A2 (es) Anticuerpos anti-ccr8 y usos de los mismos
WO2010128407A8 (en) Anti-il-17f antibodies and methods of use thereof
UY31478A1 (es) Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper

Legal Events

Date Code Title Description
FG Application granted